Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Hepatitis in 2010

The dawn of a new era in HCV therapy

Nature Reviews Gastroenterology & Hepatology volume 8, pages 69–71 (2011)Cite this article

Subjects

Although several antiviral treatments for HBV infection have recently reached the market, no direct acting antiviral drugs to treat infection with HCV have been licensed in the 20 years since its identification. Excitingly, recent publications herald several small revolutions in antiviral treatment of HCV that have considerable relevance for prospective HCV therapies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Model of HCV lifecycle and targets for antiviral therapy.

References

  1. Manns, M. P. et al. The way forward in HCV treatment—finding the right path. Nat. Rev. Drug Discov. 6, 991–1000 (2007).

    Article  CAS  Google Scholar 

  2. McHutchison, J. G. et al. Telaprevir for previously treated chronic HCV infection. N. Engl. J. Med. 362, 1292–1303 (2010).

    Article  CAS  Google Scholar 

  3. Kwo, P. Y. et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376, 705–716 (2010).

    Article  CAS  Google Scholar 

  4. Jacobson, I. M. et al. Telaprevir in combination with Peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 ADVANCE study [abstract 211]. Hepatology 52 (Suppl.), 427A (2010).

    Google Scholar 

  5. Poordad, F. et al. Boceprevir (BOC) combined with Peginterferon alfa-2B/ribavirin for treatment-naive patients with hepatitis C virus (HCV) genotype 1 SPRINT-2 final results. Hepatology 52 (Suppl.), 107A (2010).

    Google Scholar 

  6. Gane, E. J. et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376, 1467–1475 (2010).

    Article  CAS  Google Scholar 

  7. Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309, 1577–1581 (2005).

    Article  CAS  Google Scholar 

  8. Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198–201 (2010).

    Article  CAS  Google Scholar 

  9. Patel, H. & Heathcote, E. J. Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3. Gut doi:10.1136/gut.2010.217323.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Carl-Neuberg-Straβe 1, Hannover, 30625, Germany

    Sandra Ciesek & Michael P. Manns

Authors
  1. Sandra Ciesek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael P. Manns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael P. Manns.

Ethics declarations

Competing interests

M. P. Manns has been a speaker for Bristol Myers Squibb, Gilead, GlaxoSmithKline, Merck and Roche. He has been a consultant for Boehringer Ingelheim, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Merck, Novartis, Roche, Tibotec and Vertex. He has received grant/research support from Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Roche and Novartis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ciesek, S., Manns, M. The dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol 8, 69–71 (2011). https://doi.org/10.1038/nrgastro.2010.219

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2010.219

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing